15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.5B | $128M | 48.7% | 12.2% | $216M | $734M | $446M |
| 2024 | $1.4B | $120M | 47.4% | 11.5% | $186M | $730M | $377M |
| 2023 | $1.3B | $94M | 46.4% | 9.9% | $111M | $823M | $587M |
| 2022 | $1.2B | $75M | 45.1% | 7.6% | $69M | $198M | $58M |
| 2021 | $1.1B | $48M | 45.2% | 5.7% | $119M | $243M | $68M |
| 2020 | $964M | -$10M | 41.6% | -0.2% | $119M | $351M | $57M |
| 2019 | $995M | $5M | 43.5% | 1.6% | -$360000 | $439M | $44M |
| 2018 | $883M | $42M | 44.7% | 6.6% | $23M | $402M | $67M |
| 2017 | $728M | $28M | 44.8% | 4.5% | $24M | $285M | $32M |
| 2016 | $604M | $20M | 43.9% | 5.8% | $21M | $324M | $19M |
| 2015 | — | $24M | — | — | $18M | $208M | $4M |
| 2014 | — | $23M | — | — | $19M | $224M | $7M |
| 2013 | — | $17M | — | — | -$8M | $249M | $7M |
| 2011 | — | $23M | — | — | -$25M | $31M | $10M |
| 2010 | — | $12M | — | — | $11M | $82M | $4M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $382M | $41M | 48.4% | 11.6% | $25M | $735M | $488M |
| Dec '25 | $394M | $38M | 49.6% | 13.8% | $74M | $734M | $446M |
| Sep '25 | $384M | $28M | 48.5% | 11.1% | $53M | $733M | $392M |
| Jun '25 | $382M | $33M | 48.2% | 12.3% | $70M | $732M | $342M |
| Mar '25 | $355M | $30M | 48.4% | 11.5% | $20M | $731M | $396M |
| Dec '24 | $355M | $28M | 48.7% | 10.3% | $65M | $730M | $377M |
| Sep '24 | $340M | $28M | 46.4% | 11.0% | $38M | $751M | $523M |
| Jun '24 | $338M | $36M | 47.7% | 13.6% | $58M | $801M | $637M |
| Mar '24 | $324M | $28M | 46.9% | 11.1% | $25M | $800M | $582M |
| Dec '23 | $325M | $28M | 46.4% | 10.4% | $55M | $823M | $587M |
| Sep '23 | $315M | $26M | 45.1% | 11.1% | $42M | $286M | $59M |
| Jun '23 | $320M | $20M | 47.7% | 9.0% | $12M | $339M | $72M |
| Mar '23 | $298M | $21M | 46.5% | 8.9% | $2M | $198M | $58M |
| Dec '22 | $293M | $33M | 45.9% | 10.4% | $16M | $198M | $58M |
| Sep '22 | $287M | $15M | 44.8% | 6.5% | $20M | $217M | $51M |
| Jun '22 | $295M | $15M | 45.8% | 7.9% | $32M | $246M | $63M |
| Mar '22 | $275M | $11M | 43.9% | 5.5% | $2M | $252M | $54M |
| Dec '21 | $278M | $21M | 46.3% | 7.9% | $37M | $243M | $68M |
| Sep '21 | $267M | $12M | 45.1% | 6.0% | $18M | $279M | $69M |
| Jun '21 | $280M | $5M | 44.3% | 3.2% | $35M | $292M | $70M |
How the market has priced MMSI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Merit Medical Systems Inc's revenue has grown 9.5% per year. These are computed facts, not advice.
As of FY2025, Merit Medical Systems Inc reported $734M of total debt against $446M of cash; operating income covered interest expense 7.0×.
In FY2025, gross margin was 48.7%, operating margin 12.2%, and net margin 8.5%.
As of Jun '26, Merit Medical Systems Inc traded at a price-to-earnings ratio of about 32.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.